Human Immune Responses to Yellow Fever Vaccination

Phase 4 Completed 239 enrolled Emory University National Institute of Allergy and Infectious Diseases (NIAID) · collab National Institutes of Health (NIH) · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.

Timeline

Start: 2008-05
Primary completion: 2024-08-29
Completion: 2024-08-29

Publications

Results Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, Keyserling HL, Ploss A, Rice CM, Orenstein WA, Mulligan MJ, Ahmed R. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009 Dec 15;183(12):7919-30. doi: 10.4049/jimmunol.0803903.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Yellow Fever Vaccine	Vaccine	—	—

Human Immune Responses to Yellow Fever Vaccination

Summary

Timeline

Publications

Drugs

Indications